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Background: Immunotherapy changed the landscape of non-small cell lung cancer (NSCLC). Efforts were
made to implement its action. This study aims to describe body composition, nutritional and inflammatory
status in NSCLC patients treated by first-line immunotherapy, their correlation, variation and impact.
Patients and methods: We retrospectively analyzed 44 consecutive patients who received pembrolizumab
treatment. Results: During the therapy, inflammation and visceral fat increased, whereas muscle and
subcutaneous fat decreased. Parameters related to inflammation had an interesting prognostic impact.
High numbers of white blood cells remained significantly correlated with a high risk of death in
multivariate model. Conclusion: For the best treatment choice, a combination of clinical and biological
factors will be most likely be necessary. Prospective and larger studies with a multidimensional approach
are needed.
Lay abstract: Inflammation and malnutrition in cancer patients may affect the immune system and
response to therapy. We noticed an increase in inflammation and visceral fat and a decrease in muscle
and subcutaneous fat during therapy. No variation showed a significant correlation with survival. Muscle
mass, adipose tissue and body mass index do not confirm any prognostic impact or relationship with
response to therapy. More interesting results were observed with parameters related to inflammation.
Probably, for the best treatment choice, a combination of clinical and biological factors will be necessary.
Further studies with a multidimensional approach are needed to propose the best treatment and the best
support to everyone.
Tweetable abstract: Body composition, nutritional and inflammatory status changed during first-line
immunotherapy on NSCLC patients. Inflammation has interesting prognostic implications. Combined with
other factors, these clinical characteristics may be important to optimize the care of patients.
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Lung cancer is the most important cause of cancer-related death worldwide and is frequently only diagnosed at
advanced stages [1,2]. In recent years, immunotherapy (IT) has witnessed an important therapeutic change with the
approval of nivolumab, pembrolizumab (for PD-L1 positive patients) and atezolizumab in pretreated patients [3–6]
with non-small cell lung cancer (NSCLC). First-line monotherapy with pembrolizumab was approved in patients
with high PD-L1 expression (≥50%) according to Keynote 024 trial [7], while nivolumab did not obtain approval
(Supplementary Table 1) [8], and atezolizumab was approved in May 2020 by the US FDA for patients with
high PD-L1 expression and no EGFR or ALK genomic tumor aberrations [9]. Recently, the combination of
chemotherapy plus immunotherapy achieved good results both in pretreated patients and first-line setting [10–17].
Also, the combinations of nivolumab plus ipilimumab obtained OS benefit [17]. Despite this, until the end of
2019, only pembrolizumab monotherapy was approved and reimbursed in Italy as the first-line therapy for NSCLC
patients without EGFR and ALK alterations and PD-L1 expression ≥50%. Agenzia Italiana del Farmaco (AIFA)
approved a combination of pembrolizumab with platinum and pemetrexed for patients with nonsquamous NSCLC
with PD-L1 expression <50% as front-line therapy in December 2019.
Several efforts were made to understand and implement the action of IT. When the host system fights against can-
cer, body composition and balance of nutritional and inflammatory status may be important for immune system’s
function: imbalance can lead to its malfunction [18–21]. Since the 1980s, unintentional weight loss up to the state
of cachexia was related to worse prognosis in cancer patients undergoing chemotherapy [22]. In previous studies,
depletion of muscle mass and increase of adipose tissue were described in the negative condition of ‘sarcopenic
obesity’ [19,23]. Cancer sarcopenia and cachexia were sustained by inflammation in a ‘vicious circle’ that leads to an
increase in chemotherapy toxicities [24–26]. Inflammatory markers, like CRP and neutrophil-to-lymphocyte ratio
(NLR), were correlated to sarcopenia [27,28] and CRP was correlated to cancer cachexia [29].
It is of interest to focus on parameters describing sarcopenia, adipose tissue, nutritional and inflammatory status
in relation with outcome in patients treated with IT. To achieve this aim, we selected a homogeneous subgroup of
patients in first-line setting of therapy and took a picture of their current condition without the influence of other
treatments. Patients with lung cancer who received first-line pembrolizumab appear very interesting to portray
despite their complex conditions.
Some retrospective studies over the last few years, mostly by Japanese authors, have investigated this matter
using different definitions of sarcopenia and concluded with divergent results (Table 1). All authors analyzed
pretreated patients except Takada et al who included a small percentage of first-line patients (17/103) [30]. To our
knowledge, this is the first study among western patients with lung cancer who underwent first-line IT describing
their body composition and inflammatory status, their variation during IT and its relationship with outcome.
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Figure 1. L3 axial CT scan images representative of the
technique used. Using semi-automatic software, we can
apply Hounsfield unit ranges to specifically select the
muscle and the adipose components. With this method,
we can calculate the area by manually tracing the region
of interest that includes the PMA, SMA, SFA and VFA.
PMA: Psoas muscle area; SFA: Subcutaneous fat area;
SMA: Skeletal muscle area; VFA: Visceral fat area.
Patients & methods
Design of the study, inclusion criteria & methods
This retrospective and observational study involved patients consecutively treated with pembrolizumab as front-
line therapy at Centro Oncologico Modenese between July 2017 and December 2018. Patients signed informed
consent. Prior approval was obtained from the local ethic committee (prot. AOU 0019064/19, 03/07/2019) and
authorization from the Azienda Ospedaliero-Universitaria of Modena (C.E. N. 403/2019). Clinical data were
collected in a computerized database and anonymized before the analysis. Blood exams and computed tomography
(CT) scan imaging were routinely made by patients according to clinical practice. Data cutoff was 24 February 2020.
Patients were more than 18 years old, with histologically confirmed diagnosis of advanced NSCLC, received more
than one infusion of pembrolizumab according to clinical practice and were not previously treated for advanced
cancer. Available parameters considered for the analysis are reported in Table 2.
Objective of the study
The primary objective of the study was the description of the general characteristics of NSCLC patients treated by
first-line IT, especially body composition, nutritional and inflammatory status at baseline and during IT. Then, we
made a correlation between these parameters and between baseline parameters and outcome and response to IT.
Technical aspects on CT scan imaging analysis
Muscle mass and adipose tissue were measured on CT scan images routinely performed among patients before
starting immunotherapy (basal CT scan) and at first restaging (obtained a median of 2.5 months after starting
treatment, 95% CI 2–3 months, standard deviation 0.99). Axial CT scan images were analyzed by a single operator
using Advanced Workstation (AW) Server produced by General Electric (WI, USA) . In particular, the measures
were taken at the level of a single slide at the height of the transverse process of L3. Muscle area of interest was selected
in a semi-automatic manner using the range between -29 and +150 Hounsfield (HU) [58]. By positioning an elliptic
region of interest (ROI) at the level of the right psoas muscle and the subcutaneous tissue of the ipsilateral lumbar
region, the respective basal densities were assessed. Skeletal muscle index (SMI), as a measure of muscle mass,
was obtained with skeletal muscle area (SMA) normalized for patients’ height squared. Muscle attenuation (MA),
as a measure of muscle quality, was the radio-density of the SMA measured in HU. Ratio between the psoas
muscle density and the adipose subcutaneous tissue density permitted to calculate the intramuscular adipose tissue
content (IMAC) of the psoas muscle, as another measure of muscle quality. Adipose tissue area was selected in a
semi-automatic manner using the range between -180 and -30. Tissue cross-sectional areas (cm2) were calculated
by the sum of pixel given multiplying by the pixel surface area. To calculate the index, the respective areas were
normalized for patients’ height squared. Total fat index (TFI) was obtained by the sum of visceral and subcutaneous
fat areas (VFA and SFA, respectively) normalized for height squared, visceral fat index (VFI) and subcutaneous
fat index (SFI). Visceral adiposity (VSR) was VFA/SFA ratio. Figure 1 is representative of the technique used and
shows the selection of fat and muscle areas: SFA, VFA, psoas muscle area (PMA) and SMA.
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Table 2. Methods, parameters and values used in our analysis with relative references.
Body
composition




Muscle mass CT-scan at L3 Psoas muscle index x x M: 6.36; F: 3.92 Shiroyama et al. (2019) [35]
Total muscle
attenuation
x x BMI ≥25:33, 25:41 Martin et al. (2013) [37]
SMI (cm2/m2) x x M: 55; F: 39 Fearon et al. (2011) [38]
Free fat mass index
(kg/m2)
x x M: 17; F: 15 Cederholm et al. (2015) [39]
IMAC psoas x M: -0.358; F: -0.229 Kobayashi et al. (2017) [40]
Adipose tissue CT-scan at L3 Visceral fat area
(kg/cm2)
x x M: 163.8; F: 80.1 Doyle et al. (2013) [41]
Visceral fat index
(cm2/m2)
x x M: 52.9; F: 51.5 Ebadi et al. (2017) [42]
Subcutaneous fat
index (cm2/m2)
x x M: 50; F: 42 Ebadi et al. (2017) [42]
Total fat index
(cm2/m2)





x x M: 1.325; F: 0.710 Kobayashi et al. (2017) [40]
Nutritional and inflammatory status
Nutrition Clinical measure Weight loss x§ x‡ 5% and categories Fearon et al. (2011); Martin
et al. (2015)
[38,43]
Clinical measure BMI x x 25 and categories WHO (2011); Fearon
et al. 2011; Martin
et al. (2015)
[38,43,44]
Serum ALB x x n.v. 3.5–5.0 NA
Inflammation Serum Red cell distribution
width
x x n.v. 12.6–15.8 NA
Serum CRP x x n.v. 0–0.7 NA








x x 169,1 Svaton et al. (2018) [45]
Nutrition and inflammation prognostic scores
GPS Serum (derived) ALB, CRP x Points 0–2 Forrest et al. (2003) [46]
mGPS Serum (derived) ALB, CRP x Points 0–2 Proctor et al. (2011); Simmons
et al. (2015)
[47,48]
CAR Serum (derived) ALB, CRP x 0,2357 Ni et al. (2018) [49]
ALI Serum (derived),
clinical measure
BMI, ALB, CRP x 18 Ozyurek et al. (2018);
Shiroyama et al. (2018)
[50,51]
mALI Serum (derived), CT
scan at L3
SMI, ALB, CRP x 31.1 Kim et al. (2016) [52]
PNI Serum (derived) ALB, L x 45.5 Shoji et al. (2019) [53]
PI Serum (derived) CRP, WBC x Points 0–2 Kasymjanova et al. (2010) [54]
SII Serum (derived) Platelet,
neutrophils, L
x 603.5 Liu et al. (2019) [55]
CONUT Serum (derived) ALB, cholesterol, L x 2 Takamori et al. (2019) [56]
GNRI Serum (derived),
clinical measure
ALB, weight x 98 Shoji et al. (2018) [57]
†At first revaluation of the disease (median after 2 months from starting immunotherapy).
‡Measurement at the last immunotherapy’s infusion.
§ In the past 6 months.
ALI: Advance lung cancer inflammation index; CAR: CRP and ALB ratio; CONUT: Controlling nutritional status; CT: Computed tomography; F: Female; GNRI: Preoperative geriatric
nutritional risk index; GPS: Glasgow Prognostic Score; IMAC psoas: Intra-muscle adipose tissue content of psoas; L: Lymphocytes; M: Male; mALI: Modified ALI; mGPS: Modified GPS;
NA: Not applicable; n.v.: Normal value; PI: Prognostic index; PNI: Prognostic nutritional index; SII: Systemic Immune-Inflammation Index; SMI: Skeletal muscle index; WBC: White blood
cell.
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Statistical analysis
Descriptive statistics are presented as median, range and percentiles for continuous variables and values and
percentage for categorical variables. Overall survival (OS) is defined as the time from the first immunotherapy
infusion to the date of death or last follow-up. Patients alive at the last follow-up time were censored at the date of
last contact. Progression-free survival (PFS) is defined as the time from the first immunotherapy infusion to the date
of progression or last follow-up. Survival analysis was made with Kaplan–Meier method. Log-rank test was used on
survival curves to compare difference between values over and under the selected literature cut-offs or normal values
(Table 2). We calculated the receiver operating characteristic (ROC) curves of selected parameters searching the best
cut-offs for our population. However, owing to the small cases series and the lack of statistical significance of the
majority of ROC curves, we chose to rely on values already reported in the literature or normal laboratory values.
Responses to therapy were defined according to the response evaluation criteria in solid tumors (RECIST) version
1.1. Overall response rate is defined like stable disease (SD) plus partial response (PR). Wilcoxon signed-rank
test was used to create box plots and to give the median test to compare the chosen parameters with responses.
Fisher’s exact test was used to examine the differences between categorical variables. Spearman’s test was used to
examine the correlation between parameters. Univariate and multivariate analysis to determine mortality hazard
ratios (HR) were conducted using Cox proportional hazard models to identify significant predictors of mortality.
Results are reported as HRs and 95% CI. Analysis was performed using STATA 11 and MedCalc Version 19.0.3.
Results
Baseline characteristics of patients
Baseline characteristics of the 44 patients involved in the study are detailed in Table 3. In addition, we evidenced
that the large majority of patients (82%) used three or more drugs daily as concomitant medications, in particular,
66% proton pomp inhibitors and 36% antibiotics in the months before or in the first months of therapy. During IT,
73% used steroids, of which 20% were for toxicities. About a third of patients (36%) was submitted to radiotherapy
during IT. As to body composition, CT images were available for 40 patients at baseline and for 34 patients at
the first radiological evaluation (performed after a median of 90 days after IT start). With focus on muscle mass,
at baseline, we noticed that different percentage of patients had low level of SMI using different cut-offs available
in literature: 52.5% by Fearon et al. [38], 42.5% by Martin et al. [37], 55% by Mourtzakis et al. [59] and 47.5% by
Prado et al. [23].
Variation of patients’ characteristics during IT
Variations between CT scan values and blood exams at baseline and first-restaging are reported in Table 4. First
restaging was considered the first CT scans made during IT, if available, and blood exams scheduled in the same
period or earlier if patients did not undergo any imaging evaluation. We noticed an increase of parameters related
to inflammation such as white blood cell (WBC) and red blood cell distribution width (RDW) and VSR and
a decrease of parameters related to muscle mass (SMI), muscle quality (MA) and subcutaneous fat mass (SFI).
Dividing the variation rate of these parameters with the time between the treatment start and the first restaging, no
significant differences were observed, except for an increase in ALB (Supplementary Table 2). No variation of the
studied parameters showed a significant correlation with OS, but a trend was frequently noted: worse OS with a
decrease of more than 10% of SFI and an increase of more than 10% of CRP (p = 0.09 and p = 0.06, respectively;
Supplementary Figure 1).
Among three selected parameters for muscle mass (psoas area, SMA and SMI) and adipose tissue (subcutaneous
fat, visceral fat and VSR), none of the variation resulted significant in correlation with ORR and progressive disease
(PD), except for the decrease of psoas muscle area among patients with PD compared to a slight increase in the
median values of the same parameter in patients with SD or PR. Also, SMA and SMI showed a greater decrease
among patients with PD like best response, with a trend toward significance (p = 0.07; Supplementary Figure 2).
Correlation between different characteristics of patients
Spearman’s coefficients and significant p-value for correlation between different patients’ characteristics are reported
in Figure 2. Supplementary Table 3 reported all values calculated. Interesting correlations were those regarding
parameters not included or combined in the formula for scores’ calculation. For example, age was related with
muscle quality (total MA), BMI with muscle mass (SMI), ALB with muscle quality (total MA) and inflammatory
parameters (WBC, CRP, NLR and Systemic Immune-Inflammation Index [SII]) and CRP with inflammatory and
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Table 3. Baseline characteristics of patients regarding general characteristics, nutritional status, body
composition, inflammatory status and nutritional and inflammatory scores.
General characteristics (n = 44) n %









Past smoker 27 61.4
Current smoker 16 36.4
Metastatic sites
Lung and pleura 19 43.2










Squamous cell carcinoma 10 22.7
Other 5 11.4
Molecular abnormalities (N with available data)
K-RAS (n = 34) 13 38.2
EGFR (n = 35) 0 0
ALK (n = 35) 1 2.9
BRAF (n =34) 3 8.8
PD-L1 values (n = 43) median (range) 70 (55–95)
Nutritional status (n = 44)
Weight at start IT median (kg) (range) 65 (41–103)
BMI median (kg/m2) (range) 23.5 (15.7–32.5)
BMI categories, (kg/m2) sec WHO
Underweight: 18.5 4 9.1
Normal: 18.5–24.9 29 65.9
Overweight: 25.0–29.9 7 15.9
Obese: ≥30 4 9.1






Weight loss before start IT (n = 41) ≥5% in 6 months 8 18.2
ALB (g/dl), median (range) 3.55 (2–4.9)
ALI: Advance lung cancer inflammation index; BMI: Body mass index; CONUT: Controlling nutritional status; GNRI: Preoperative geriatric nutritional risk index; GPS: Glasgow
Prognostic Score; IMAC psoas: Intra-muscle adipose tissue content of psoas; IT: Immunotherapy; mALI: Modified ALI; mGPS: Modified GPS; NLR: Neutrophil-to-lymphocyte
ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic Nutritional Index; SMI: Skeletal muscle index.
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Table 3. Baseline characteristics of patients regarding general characteristics, nutritional status, body
composition, inflammatory status and nutritional and inflammatory scores (cont.).
Nutritional status (n = 44)
Basal Body composition characteristics (n = 40) Median (Range)
Muscle
Psoas area 12 (6.6–29.6)
Psoas muscle index 4.5 (2.8–10)
Region of interest psoas 53.4 (32.6–72.7)
Total muscle attenuation 34 (13–51.6)
Total skeletal muscle area 122.2 (77.8–180.2)
SMI – Total
– Male (n = 23)




Free fat mass 42.7 (29.4–60.1)
Free fat mass index 15.9 (11.6–22.2)
IMAC psoas -0.5 (-1—0.3)
Adipose tissue
Visceral fat area 130.1 (13.9–476.7)
Visceral fat index 48.4 (5.2–139.3)
Subcutaneous fat area 135.6 (33.7–261.1)
Subcutaneous fat mass 47.1 (13.2–104.8)
Region of interest subcutaneous tissue -103.8 (-126.1—64.2)
Total fat index 96.6 (18.8–209.5)
Fat mass 22.6 (13.2–39.2)
Fat mass index 8 (4.8–13.8)
Visceral adiposity 0.9 (0.2–3.4)
Inflammatory status (n data available) Median (Range)
Blood exams
White blood cell (/mmc) (n = 44) 9425 (3980–43770)
Neutrophils (/mmc) (n = 44) 7022.5 (1830–40250)
Red blood cell distribution width (cv%) (n = 44) 14.3 (12.5–21.3)
CRP (mg/dl) (n = 37) 2.6 (0.2–23.3)
Blood derived data
NLR (n = 32) 5 (1.2–18.4)
PLR (n = 32) 179.1 (97.1–864.2)
Nutritional and Inflammatory scores (N data available) Values or Median (Range)
Inflammation
GPS (n = 37) 14 (0), 17 (1), 6 (2 points)
mGPS (n = 37) 27 (0), 4 (1), 6 (2 points)
Prognostic Index (n = 44) 24 (0), 14 (1), 6 (2 points)
CRP and ALB ratio (n = 37) 0.1 (0–0.9)
Systemic Immune-Inflammation Index (n = 32) 1366.3 (206.5–9947.1)
ALI (n = 32) 16.6 (3.6–70.6)
mALI (n = 28) 29.3 (6.4–128.6)
Nutrition
PNI (n = 32) 42.1 (27.8–60.3)
CONUT (n = 17) 3 (0–10)
GNRI (n = 44) 96.2 (59.5–122.8)
ALI: Advance lung cancer inflammation index; BMI: Body mass index; CONUT: Controlling nutritional status; GNRI: Preoperative geriatric nutritional risk index; GPS: Glasgow
Prognostic Score; IMAC psoas: Intra-muscle adipose tissue content of psoas; IT: Immunotherapy; mALI: Modified ALI; mGPS: Modified GPS; NLR: Neutrophil-to-lymphocyte
ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic Nutritional Index; SMI: Skeletal muscle index.
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Table 4. Variation of blood exams and CT scan values from baseline to first restaging†.
Total variation rate Median of variation rate (%)‡ % increase ≥10% % decrease ≥10%
Blood exams (44 available)
WBC ↑ 1.3 40.9 36.4
RDW ↑ 2.8 36.4 4.5
ALB = 0 22.7 15.9
CT scan values (34 available)
SMI ↓ -3.1 2.9 32.4
MA ↓ -2.0 20.6 29.4
SFI ↓ -6.7 29.4 35.3
VFI = +0.3 38.2 35.3
VSR ↑ +5.5 38.2 17.6
†First restaging: CT scan of first revaluation (obtained a median of 2.5 months after starting treatment, 95% CI 2–3 months, standard deviation 0.99); blood exams in the same period of
the first CT scans or earlier if patient did not undergo any imaging revaluation.
‡Variation rate = (value at time of first revaluation – value at baseline) × 100/value at baseline.
↑ Increase; ↓ Decrease; = Stable.
MA: Muscle attenuation; RDW: Red blood cell distribution width; SFI: Subcutaneous fat index; SMI: Skeletal muscle index; VFI: Visceral fat index; VSR: Visceral adiposity; WBC: White blood
cell.
nutritional scores (SII, ALI, mALI, PNI and GNRI) and visceral adiposity (VSR) with inflammatory parameters
(NLR, PLR, SII and ALI). In addition to the already cited correlation, muscle quality (total MA) was related
with adipose tissue (SFI and VFI), muscle mass (SMI and psoas area) and PNI and muscle mass (SMI) with the
nutritional score GNRI.
Outcome with immunotherapy
Median follow-up time was 265 days. Median overall survival (mOS) was 9.01 months (90% CI 6.1-17.2
months; Figure 3A). Lack of patients selection may have influenced the result, but we observed a good per-
centage of patients in the ‘tail’ of the curve with a longer follow-up. One- and two-year OS rates were 45% (95%
CI 33–60%) and 40% (95% CI 24–54%) respectively. Median progression free survival (mPFS) was 5.6 months
(90% 4.3–7.7 months; Figure 3B). One-year PFS was 41% (95% CI 26–55%). There were five patients still on
IT without PD and four stopped for toxicities or for physicians’ or patient’s decision without PD. Post-PD, one
quarter of patients received chemotherapy, all with platinum doublet, the remaining started best supportive care.
Investigating general characteristics in relation with survival: sex (male vs female), age (<65 vs ≥65 years old and
<75 vs ≥75 years old), Eastern Cooperative Oncology Group (ECOG ; 0–1 vs ≥2), presence of CNS metastasis
(yes vs no, however there were only six patients with CNS metastasis in our analysis), weight loss (WL) (≥5% in
6 months vs <5%) and BMI (≤25 vs >25) were not statistically significant correlated with survival in our patients
series. Antibiotics use in the month before or in the first month of IT was associated with worse OS (p = 0.0012),
whereas PPI use did not relate with it. None of the CT scan images parameter, neither about muscle mass nor
adipose tissue, confirmed in our analysis a significant prognostic role. However, patients with a higher muscle mass
(PMI, SMI, FFMI above the literature cut-offs) and a better muscle quality (higher muscle density, higher MA and
IMAC) have a trend of better OS compared with others. Also, those with a higher SFI and TFI have a little trend of
better OS. Regarding blood exams, a good prognostic value was confirmed for normal WBC, neutrophils, and ALB
(p = 0.0217, p = 0.0121 and p = 0.0308, respectively). No significance was found for NLR, PLR, CRP and RDW.
Among nutrition and inflammation scores in our study, PI, ALI and mALI confirmed a significant prognostic
role: low PI score (divided between 0 and 1–2 points) was associated with better survival (p = 0.0031) and low
ALI (<18) [50,51] and low mALI (<31.1) [52] were associated with worse survival (p = 0.0321 and p = 0.0446,
respectively). Moreover, ROC curves of selected parameters and related Kaplan–Meier OS curves with both values
derived from ROC curves, medians and values derived from literature or normal laboratory values are reported in
Supplementary Figures 3 & 4. We observed a similar trend among different Kaplan–Meier OS curves. This fact,
though frequently without statistically significance, may reinforce the hypothesis that the results were due to the
parameters rather than to the cut-offs used. However, the importance of the choice of the optimal cut-offs has to
be underlined. We chose, mostly due to the small number of our case series, to rely on cut-offs already used for the
main analysis. The use of medians may be another option, but statistical significance of the data were not always
improved (as in Supplementary Figure 3). Univariate and Multivariate analysis on selected parameters calculated
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Parameters combined in formula
Parameters included in formula
Correlation
Figure 2. Correlation between different characteristics of patients.
ALI: Advance lung cancer inflammation index; CAR: CRP and ALB ratio; GNRI: Preoperative geriatric nutritional risk
index; IMAC p: Intra-muscle adipose tissue content of psoas; MA: Muscle attenuation; mALI: Modified advance lung
cancer inflammation index; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PNI: Prognostic
nutritional index; Psoas A: Psoas muscle area; SFI: Subcutaneous fat index; SII: Systemic Immune-Inflammation Index;
SMI: Skeletal muscle index; VFI: Visceral fat index; VSR: Visceral adiposity; WBC: White blood cell.
with Cox proportional hazard model are reported in Table 5. In Univariate analysis ECOG, WBC, ALB, ALI
and PI were significantly correlate with survival. In our multivariate model with the analysis of single parameters,
without scores, high WBC remained significantly correlate with a high risk of death. Moreover, high BMI had
a trend toward a low risk of death and higher VSR (like continuous variable) showed a trend toward a high risk
of death. Considering WBC, ALB, CRP and NLR as continuous variables, the same evidence was confirmed in
both univariate and multivariate analyses, though ALB lost significance in univariate analysis (Supplementary Table
4). All the results need to be considered with caution because of the reduced number of cases in the model.
ORR in our series was 56% (0 complete response + 32% PR + 24% SD). Best response was PD in 44% of
patients. No significant correlations were found between four baseline characteristics (two from CT scan imagines:
SMI for investigate muscle mass and VSR for adipose tissue and two from blood exams: ALB for nutritional status
and CRP for inflammatory status) and response (Supplementary Figure 5).
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Figure 3. Overall Survival and progression-free survival in our patients. (A) Kaplan–Meier overall survival and (B)
progression-free survival in our patients with 95% CI and number at risk under curves. Time in months.
Discussion
Inflammation has a prognostic role in some types of cancer and especially in those tumors where IT was first
developed, like melanoma [60] and renal cell carcinoma [61]. It has to be underlined that the concept of inflammatory
state used in our analysis has no relationship with the inflammatory state of the tumor and its microenvironment.
Our analysis was based on clinical parameters without analyzing the biology of the tumor.
Our data confirmed that inflammatory status, investigated with different blood exams and scores, had prognostic
significance in NSCLC patients treated by first-line IT. We could not refer specifically about its predictive value
because our analysis lacks a comparison group, even if a predictive value may be supposed.
The PI score [54] based on CRP and WBC seemed superior in differentiating good from poor prognostic groups
compared to the scores based on combination of circulating white cell count (NLR, PLR) or lymphocytes and
ALB (PNI) [53]. These latter parameters did not reach statistical significance in our analysis. Scores combining
CRP, ALB and body composition in term of BMI (ALI score) [50,51] and SMI (mALI) [52] performed well in
giving prognostic information. CRP seemed to be a fundamental component to define prognosis on this group of
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Table 5. Overall survival univariate and multivariate analysis with different baseline parameters.
Characteristics Variables HR 95% CI p-value
Univariate analysis
ECOG 2 vs 0–1 2.30 1.01–5.02 0.036
Sex Female vs male 0.78 0.37–1.67 0.527
Smoking status No or former vs yes 0.72 0.33–1.56 0.408
Age (years) ≤65 vs 65 0.81 0.37–1.80 0.609
BMI 25 vs ≤25 0.54 0.21–1.44 0.218
Met CNS yes vs no 2.40 0.90–6.39 0.079
WBC high vs normal 2.34 1.11–4.96 0.026
ALB low vs normal 2.25 1.05–4.80 0.035
CRP high vs normal 2.36 0.81–6.90 0.117
NLR high vs normal 1.57 0.67–3.62 0.292
PLR high vs normal 1.51 0.65–3.47 0.331
Total MA like continuous variable 0.96 0.92–1.01 0.117
SMI like continuous variable 1 0.98–1.01 0.618
VSR like continuous variable 1 0.67–2.34 0.511
ALI c.o. vs ≥c.o. (c.o. = 18) 2.54 1.05–6.13 0.038
mALI c.o. vs ≥c.o. (c.o. = 31.1) 2.43 1–5–9.5 0.051
PI 1–2 vs 0 points 3.06 1.40–6.67 0.005
PNI ≤c.o. vs c.o. (c.o. = 45.1) 1.86 0.76–4.56 0.173
Multivariate analysis
ECOG 1.76 0.69–4.56 0.237
WBC 3.65 1.40–9.49 0.008
ALB 1.38 0.59–3.21 0.453
BMI 0.35 0.12–1.03 0.056
SMI 0.99 0.98–1.02 0.949
VSR 1.83 0.93–3.57 0.077
ALI: Advance lung cancer inflammation index; c.o.: Cutoff; ECOG: Eastern Cooperative Oncology Group; HR: Hazard ratio; mALI: Modified advance lung cancer inflammation index; PI:
Prognostic index; PNI: Prognostic nutritional index; SMI: Skeletal muscle index; VSR: Visceral adiposity; WBC: White blood cell.
patients and normal values confirmed a better prognostic significance, as reported in the literature [62,63]. Normal
WBC count and ALB values also had a positive prognostic significant. The recent retrospective study published
by Matsubara et al., instead, found that PNI was an independent predictor of short time to treatment failure in
NSCLC patients treated with atezolizumab and high NLR and high mGPS were independent prognostic factor
for OS in this population [64].
Analysis of body composition both in muscle and in adipose tissue components, instead, did not confirm
prognostic significance in our analysis. High values of parameters of muscle quantity (SMI) and quality (total MA)
showed a trend of good prognostic significance, but without obtaining significant values. The same results on
baseline skeletal muscle mass were recently published by Cortellini et al [31]. The major limitation of our analysis
could be found in the low number of cases evaluated and the same limits was reported in the cited published study
too [31]. In combination with other known important values, they reached the statistical significance (mALI). Also
combined with other CT scan parameters, muscle mass has been reported to have a prognostic significance in
patients treated by IT for different cancers, principally melanoma: a prognostic score based on CT scan analysis has
been proposed. It includes tumor burden (1 point if >90 mm), SMI (1 point if <53 cm/m2) and nonpulmonary
visceral metastasis (1 point if >2). The score predicts clinical benefit on anti-PD-1/PDL-1 therapy, independently
from other conventional clinical-biological prognostic scores [65]. Another point of discussion is the different
percentage of patients with low muscle mass that we found using the different cut-offs validated in the literature
(excluding Asian cut-offs which are still different). The possibility of using different measures to assess sarcopenia,
because of the non-univocal agreement, makes studies on the matter difficult to be compared. Adipose tissue
parameters, on the other hand, appear to be distant from having a significant prognostic role, particularly if
considered alone. There is little information in literature on the subject, except for the work by Ebadi et al [42].
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Finally, considering the methods of body composition measurements, not dwelling on different techniques like
bioelectrical impedance analysis (BIA) or dual energy x-ray absorptiometry (DXA), on CT or MRI, it has to be
underlined that the limitations of a 2D measurement are known. For example, it has been shown that during weight
loss, changes in visceral and subcutaneous adipose tissue are poorly assessed by a single slice (2D imaging) [66], while
3D imaging works well for fat [67]. Despite this, the 2D measurements techniques are still widely used in literature
and in our center, we have the availability of this program.
BMI and weight loss deserve a special consideration. Probably, again owing to the small simple size, neither
of them achieved statistical significance as prognostic factors in our study. Even if a trend could be described,
we did not observe a significant ‘obesity paradox’, described instead in literature in different cancer types [68–70]
including melanoma treated with immunotherapy and target therapy (but not with chemotherapy) [71]. Moreover,
an Italian study involving different cancer types documented higher response rate and survival in overweight/obese
patients [72]. However, when the patients were divided into various classes according to Martin et al. [43], BMI and
weight loss showed significant value on overall survival in our analysis (Supplementary Figure 6). We cannot study
the particular condition of ‘sarcopenic obesity’ specifically because we have only 11 patients with BMI ≥25 of whom
three with the criteria of sarcopenia and only four with BMI ≥30 of whom one with ‘sarcopenic obesity’. This
phenomenon combines low muscle mass and high fat mass and was associated in literature with worst outcome [23]
and more toxicity to IT [73].
Our data did not evidence a better outcome among female patients compared with male patients, showing only a
possible trend, even if it was described in literature and reported in the meta-analysis by Conforti et al [74]. Neither
ECOG PS reached statistical significance as prognostic factor, even it has known importance. Perhaps, an interesting
analysis could be on the causes of an expired performance status: for burden/disease or for comorbidities. For the
small number of cases from our series we could not draw conclusion based on our monocenter study, but we have
participated to a large multicenter retrospective trial evaluating several clinic-pathological characteristics in relation
with first-line pembrolizumab effectiveness that showed ECOG PS, bone and liver metastases as independent
predictors of shortened OS [75].
The use of antibiotics in the near period before or at the start of IT had a negative prognostic role on survival in
our analysis. The same evidence has been reported [76,77] and underlined in a recent meta-analysis [78], demonstrating
the scientific interest on the role of antibiotics in modifying the gut microbiome in relation with the efficacy of IT.
Our response rate (PR 32%) is lower than that reported in the literature (Keynote 024 study [7] had objective
response of 44.8%), but we have consecutive as well as nonselected patients. Neither body composition baseline
parameters (SMI for muscle mass and VSR for adipose tissue) nor blood baseline exams related to inflammatory
status (ALB and CRP) correlated with response (ORR and PD).
Only the variation of muscle psoas area, between the investigated parameters, during first-line IT showed a
significant association with response (divided between ORR and PD). SMA and SMI in the PD group showed a
trend of greater decline (but not statistically significant).
The present results underline the importance of the systemic inflammatory response as a connecting factor
between nutritional decline and poor outcome in cancer patients, as shown in previous studies that investigated
the role of inflammatory scores [46,79]. Systemic inflammation may act as a ‘common soil’ promoting cancer
progression [80] and its moderation may be important. In this scenario, systemic inflammation and body composition
deterioration may not be faced by IT alone, but it will be probably necessary a multidrug and a multimodal
approach to fight all aspects and to maximize treatments’ effect. A detailed study on inflammation process in cancer
is required to improve the efficacy of IT and to upgrade its function, which is established on the immune system
and on a well-balanced host body.
From our data and literature analysis, we cannot draw definitive conclusions. However, we can speculate that
inflammation has its role either alone and in combination with nutritional status and body composition for affecting
the immune response against cancer and even more in the setting of IT. The negative role of body composition
alterations on declining immunity has already been proposed [81]. Skeletal muscle interacts with immune response [82]
and products IL-15, necessary for natural killer (NK) cell function [83]. These cells, expressing PD1, if activated
in the tumor site, may be important in the action of anti PD1/PDL1 antibodies [84]. Adipose tissue has a known
endocrine and inflammatory role for influencing tumor behavior [85]. An attempt to explain the double face of
obesity, the increased risk of cancer and the apparently increased efficacy of PD1/PDL1 blockade, was made by
Wang et al., on leptin signaling, T-cell aging with higher PD1 expression and dysfunction [86].
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Conclusion
The vicious circle of chronic inflammation and malnutrition leading to sarcopenia and cachexia in cancer patients
affects the immune system and response to therapy. IT, with its mechanism and complexity, has received significant
attention because of the relevance of nutritional and inflammatory assessment for patients at baseline. Clinical
parameters alone, however, do not include all aspects related to response to therapy and patients outcome. The
lack of investigation of biological factors, such as PD-L1 and tumor mutational burden, in our analysis has to
be underlined. We focus our attention on impact of body composition and inflammatory status (investigated
with clinical parameters) in the setting of NSCLC patients treated by first-line IT. Probably, one universal and
unique tool for the choice of the best treatment for every patient does not exist in this field, different from those
cancers with a driver mutation or a driver molecular pathway to target. Important efforts were made by scientific
communities to find various prognostic and predictive tools to use in treatment’s choice. In the IT setting, either
alone or in combination with other strategies, the best choice will be probably the combination of clinical and
biological factors. To make a careful patients’ screening before starting treatment and also an accurate patients’
selection, incorporating early palliative care strategies to ‘help’ standard therapy should be the best strategy. Further
clinical trials are required, possibly prospective and multicenter, to expand knowledge in the IT field combining
clinical and biological factors each other and with preclinical and analytic studies. A step in the future IT will
be the study of different lymphocytic subtypes and other cellular and noncellular components of the immune
response against cancer and their dynamics during treatment. Two studies are ongoing in our center on this
topic on melanoma and renal cell carcinoma. It will be interesting to investigate these aspects also in patients
with different nutritional disorders, up to sarcopenia and cachexia, with the aim to research which components
readily respond, which ones need to be stimulated to obtain an effective anti-tumor response, and which are not
responded or exhausted in different patients’ conditions. A multimodal approach based on nutritional, exercise
and anti-inflammatory strategies should be subsequently studied to improve these aspects of the immune response
against cancer to achieve maximum results in all patients and to propose the best treatment and/or the best support
to everyone.
Summary points
• Inflammation and malnutrition in cancer patients may affect the immune system and response to therapy. The
study of non-small cell lung cancer patients who have undergone first-line immunotherapy (IT) is interesting for
these aspects.
• We noticed an increase in inflammation and visceral fat and a decrease in muscle mass, muscle quality and
subcutaneous fat during therapy. No variation showed a significant correlation with survival.
• Muscle mass, adipose tissue and body mass index do not confirm a prognostic impact or relationship with
response to therapy. More interesting results were observed with parameters related to inflammation.
• The use of antibiotics in the near period before or at the start of IT had a negative prognostic role on survival in
our analysis.
• Neither body composition baseline parameters nor blood baseline exams related to inflammatory status
correlated with response to IT, and only the variation of muscle psoas area during therapy showed a significant
association with response.
• We can speculate that inflammation has its role either alone or in combination with nutritional status and body
composition in affecting the immune response against cancer and even more in the setting of IT.
• Probably, for the best treatment choice, a combination of clinical and biological factors are necessary.
• Prospective and larger studies are needed with a multidimensional approach to propose the best cure and care to
everyone.
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